BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 215 filers reported holding BLUEPRINT MEDICINES CORP in Q1 2023. The put-call ratio across all filers is 2.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $24,420,792 | +17.9% | 226,580 | +3.7% | 0.09% | +19.7% |
| Q1 2024 | $20,720,839 | +59.3% | 218,436 | +54.9% | 0.08% | +49.0% |
| Q4 2023 | $13,004,825 | +599.0% | 140,989 | +240.9% | 0.05% | +466.7% |
| Q1 2023 | $1,860,426 | -31.0% | 41,352 | +1.0% | 0.01% | -40.0% |
| Q3 2022 | $2,697,000 | -8.1% | 40,927 | -29.6% | 0.02% | 0.0% |
| Q2 2022 | $2,936,000 | +27.0% | 58,132 | +121.3% | 0.02% | -6.2% |
| Q2 2021 | $2,311,000 | +21.4% | 26,268 | +34.2% | 0.02% | +14.3% |
| Q1 2021 | $1,903,000 | -85.9% | 19,575 | -83.7% | 0.01% | -87.6% |
| Q4 2020 | $13,470,000 | +727.9% | 120,104 | +584.4% | 0.11% | +707.1% |
| Q3 2020 | $1,627,000 | +525.8% | 17,550 | +294.0% | 0.01% | +100.0% |
| Q1 2020 | $260,000 | -74.8% | 4,454 | -65.4% | 0.01% | -65.0% |
| Q4 2019 | $1,032,000 | -53.3% | 12,882 | -45.1% | 0.02% | -67.2% |
| Q2 2019 | $2,212,000 | +37.3% | 23,450 | -26.3% | 0.06% | +52.5% |
| Q2 2017 | $1,611,000 | – | 31,800 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 559,381 | $41,098,000 | 15.69% |
| Casdin Capital, LLC | 940,000 | $69,061,800,000 | 7.15% |
| Ghost Tree Capital, LLC | 325,000 | $23,878,000 | 6.08% |
| CADIAN CAPITAL MANAGEMENT, LP | 1,418,704 | $104,232,000 | 4.96% |
| DAFNA Capital Management LLC | 123,218 | $9,053,000 | 3.40% |
| BVF INC/IL | 437,565 | $32,148,000 | 3.38% |
| Opaleye Management Inc. | 105,000 | $7,714,000 | 2.79% |
| Cormorant Asset Management, LP | 493,000 | $36,221,000 | 2.20% |
| Novo Holdings A/S | 170,667 | $12,539,000 | 2.15% |
| Artal Group S.A. | 600,000 | $44,082,000 | 1.77% |